New weekly shot aims to turn back the clock on prediabetes

NCT ID NCT07654062

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a once-weekly injectable drug called mazdutide can help adults with prediabetes achieve normal blood sugar levels. About 150 participants will receive either a low dose, a higher dose, or a placebo for 24 weeks, along with diet and exercise advice. The main goal is to see how many people return to healthy blood sugar after treatment, with a 24-week follow-up to check if the effects last.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
mazdutide (a once-weekly injectable drug that activates GLP-1 and glucagon receptors to lower blood sugar and weight)
What this could lead to
If successful, mazdutide could offer a new option to help people with prediabetes return to normal blood sugar levels and potentially prevent or delay type 2 diabetes.
What could go wrong
This is a relatively small, early-phase trial (Phase 4) with only 150 participants, so results may not apply to everyone. The drug may cause side effects like nausea or injection-site reactions, and benefits may not last after treatment stops.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMPAIRED FASTING GLUCOSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glucose intolerance Insulin Resistance prediabetes syndrome Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shandong Provincial Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, 250021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.